Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis

British Journal of Dermatology

Volumn 153, Issue 5, 2005, Pages 900-910

  Ho, C K ^a   Li, Gang ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JACK BELL RESEARCH CENTRE   (Canada)

Author keywords

Apoptosis; CP 31398; Melanoma; p53

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 9; CYTOCHROME C; MUTANT PROTEIN; PROTEIN BAX; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL MEMBRANE POTENTIAL; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG SENSITIVITY; ENZYME DEGRADATION; ENZYME RELEASE; HEALTH STATUS; HUMAN; HUMAN CELL; MELANOMA CELL; MITOCHONDRIAL MEMBRANE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; REVERSE TRANSCRIPTION; REVERTANT; TUMOR CELL LINE; WILD TYPE;

APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CASPASE 3; CASPASE 9; CASPASES; CELL SURVIVAL; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, P53; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA; MEMBRANE POTENTIALS; MITOCHONDRIA; PROTEINS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27544493820     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06810.x     Document Type: Article

References (55)

1. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998; 12:2984-91.
2. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10:1054-72.
3. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998; 12: 2973-83.
4. Asker C, Wiman KG, Selivanova G. p53-induced apoptosis as a safeguard against cancer. Biochem Biophys Res Commun 1999; 265:1-6.
5. Li G, Ho VC, Mitchell DL et al. Differentiation-dependent p53 regulation of nucleotide excision repair in keratinocytes. Am J Pathol 1997; 150:1457-64.
6. Tron VA, Trotter MJ, Ishikawa T et al. p53-dependent regulation of nucleotide excision repair in murine epidermis in vivo. J Cutan Med Surg 1998; 3:16-20.
7. Beroud C, Soussi T. p53 gene mutation: software and database. Nucleic Acids Res 1998; 26:200-4.
8. Li G, Bush JA, Ho VC. p53-dependent apoptosis in melanoma cells after treatment with camptothecin. J Invest Dermatol 2000; 114:514-19.
9. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31.
10. Lowe SW, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-10.
11. Lowe SW. Cancer therapy and p53. Curr Opin Oncol 1995; 7:547-53.
12. Weinstein JN, Myers TG, O'Connor PM et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 275:343-9.
13. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1:68-76.
14. Selivanova G, Kawasaki T, Ryabchenko L et al. Reactivation of mutant p53: a new strategy for cancer therapy. Semin Cancer Biol 1998; 8:369-78.
15. Foster BA, Coffey HA, Morin MJ et al. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286:2507-10.
16. Rippin TM, Bykov VJ, Freund SM et al. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002; 21:2119-29.
17. Takimoto R, Wang W, Dicker DT et al. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002; 1:47-55.
18. Luu Y, Bush J, Cheung KJ Jr et al. The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. Exp Cell Res 2002; 276:214-22.
19. Bykov VJ, Issaeva N, Shilov A et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8:282-8.
20. Tanner S, Barberis A. CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity. J Negat Results Biomed 2004; 3:5.
21. Byers HR, Etoh T, Doherty JR et al. Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol 1991; 139:423-35.
22. Li G, Ho VC, Trotter MJ et al. p53 mutation in metastatic melanomas and primary melanomas from sun-exposed and sun-protected sites. J Eur Acad Dermatol Venereal 1995; 4:48-53.
23. Albino AP, Vidal MJ, McNutt NS et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994; 4:35-45.
24. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-12.
25. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76:4350-4.
26. Burnette WN. 'Western blotting': electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 1981; 112:195-203.
27. Kim HJ, Mun JY, Chun YJ et al. Bax-dependent apoptosis induced by ceramide in HL-60 cells. FEBS Lett 2001; 505:264-8.
28. Butt AJ, Firth SM, King MA et al. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000; 275:39174-81.
29. Wang W, Takimoto R, Rastinejad F et al. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003; 23:2171-81.
30. Hupp TR, Lane DP, Ball KL. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J 2000; 352:1-17.
31. Gamble J, Milner J. Evidence that immunological variants of p53 represent alternative protein conformations. Virology 1988; 162:452-8.
32. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-9.
33. Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9:1799-805.
34. Miyashita T, Harigai M, Hanada M et al. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54:3131-5.
35. Wang X, Gorospe M, Huang Y et al. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997; 15:2991-7.
36. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7:683-94.
37. Yu J, Wang Z, Kinzler KW et al. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 2003; 100:1931-6.
38. Li PF, Dietz R, von Harsdorf R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J 1999; 18:6027-36.
39. Zhang D, Berry MD, Paterson IA et al. Loss of mitochondrial membrane potential is dependent on the apoptotic program activated: prevention by R-2HMP. J Neurosci Res 1999; 58:284-92.
40. Karpinich NO, Tafani M, Rothman RJ et al. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 2002; 277:16547-52.
41. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999; 399:483-7.
42. Cryns V, Yuan J. Proteases to die for. Genes Dev 1998; 12:1551-70.
43. Kannan K, Amariglio N, Rechavi G et al. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001; 20:2225-34.
44. Moroni MC, Hickman ES, Denchi EL et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001; 3:552-8.
45. Robles AI, Bemmels NA, Foraker AB et al. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 2001; 61:6660-4.
46. Soengas MS, Capodieci P, Polsky D et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409:207-11.
47. Roses DF, Karp NS, Oratz R et al. Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet 1991; 172:262-8.
48. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 2000; 910:121-37; discussion 137-9.
49. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000; 60:249-71.
50. Bykov VJ, Selivanova G, Wiman KG. Small molecules that reactivate mutant p53. Eur J Cancer 2003; 39:1828-34.
51. Luu Y, Li G. The p53-stabilizing compound CP-31398 enhances ultraviolet-B-induced apoptosis in a human melanoma cell line MMRU. J Invest Dermatol 2002; 119:1207-9.
52. Yu D, Jing T, Liu B et al. Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998; 2:581-91.
53. Narita M, Shimizu S, Ito T et al. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Nad Acad Sci USA 1998; 95:14681-6.
54. Pearson AS, Spitz FR, Swisher SG et al. Up-regulation of the proapoptotic mediators Bax and Bak after adenovirus-mediated p53 gene transfer in lung cancer cells. Clin Cancer Res 2000; 6:887-90.
55. Zanon M, Piris A, Bersani I et al. Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res 2004; 64:7386-94.